Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203852 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomic Evaluation of Antihypertensive Responses 2
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 839
- Enrollment target
NCT01203852: Completed Phase 4 study, sponsored by University of Florida.
NCT01203852 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 839 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203852, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 839 participants
- Enrollment target
Study Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Primary Outcome
Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment
Interventions
- DRUG Chlorthalidone
- DRUG Metoprolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
What the finished NCT01203852 record still lists
NCT01203852 is an interventional study that assigns participants to a tested intervention. The registered 839 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 2 interventions - of which Chlorthalidone is the first listed.
NCT01203852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01203852 about?
NCT01203852 is a clinical study titled "Pharmacogenomic Evaluation of Antihypertensive Responses 2". There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that g...
What is the current status of trial NCT01203852?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 839 participants. The study started on 2010-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01203852?
The interventions under investigation include: Chlorthalidone (DRUG), Metoprolol (DRUG).
Who is sponsoring clinical trial NCT01203852?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01203852's enrollment target sits among peer trials
839 90th of 2000 higher than 1,911 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia